Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence

Drug Design, Development and Therapy
Kenichi MorikawaNaoya Sakamoto

Abstract

Treatments for hepatitis C virus (HCV) have advanced greatly, becoming more efficacious with fewer adverse events, due to the availability of direct-acting antiviral agents, which target specific steps in the HCV life cycle. Recently, a combination regimen consisting of the HCV nonstructural protein 5A inhibitor elbasvir (EBR) and the HCV NS3/4A protease inhibitor grazoprevir (GZR) was approved for the treatment of patients with chronic HCV and genotypes (Gts) 1 and 4 in various countries. In Phase III trials, the combination of EBR/GZR (fixed-dose combination table or single agent) for 12 or 16 weeks of treatment with or without ribavirin resulted in a high sustained virological response at 12 weeks in treatment-naïve and treatment-experienced patients with HCV Gt 1a, 1b, 4, or 6, including special populations, such as individuals with advanced chronic kidney disease, HCV-HIV coinfection, and compensated cirrhosis. In this review, we focus on the mode of action, pharmacokinetics, clinical applications, efficacy, and safety profile of EBR/GZR, including special populations who have been considered refractory from the extensive evidence of clinical trials.

Citations

Oct 11, 2019·Journal of Medical Virology·Tzu-Cheng TsaiChao-Wei Hsu
Feb 14, 2020·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Giovanni GuaraldiUNKNOWN SHIVER Network
May 10, 2020·Liver International : Official Journal of the International Association for the Study of the Liver·Armand AbergelBenjamin Buchard

❮ Previous
Next ❯

Software Mentioned

EDGE TE
WORTHY
EDGE

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Lamis R KaraouiElias B Chahine
Expert Review of Clinical Pharmacology
Mohamed El KassasGamal Esmat
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Jerika T Lam, Laura Salazar
© 2022 Meta ULC. All rights reserved